Target Validation Information
TTD ID	T13251
Target Name	Interleukin-12 alpha (IL12A)
Type of Target	Successful
Drug Potency against Target	STA-5326	Drug Info	IC50 = 1 nM	[1]
Action against Disease Model	ABT-874	Drug Info	ABT-874 inhibited the binding of radiolabeled IL-12 to the IL-12R on phytohemagglutinin (PHA)-activated lymphoblasts with an IC50 value of approximately 11 pM, and inhibited IL-12-stimulated PHA-activated lymphoblast proliferation with an IC50 value of approximately 10 pM. ABT-874 also suppressed h uMan IFN|??production from IL-12-stimulated, PHA-activated lymphoblasts with an IC50 value of approximately 5 pM. In a mouse model, ABT-874 (16 ng/kg to 50 |?g/kg ip, on days 0, 2 and 4) dose-dependently inhibited IFN|??production induced by injection of a chimeric IL-12 protein	[2]
References
REF 1	Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood. 2007 Feb 1;109(3):1156-64.
REF 2	ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Curr Opin Investig Drugs. 2008 May;9(5):515-22.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.